Lagging, M.

patient genotype treatment hepatitis response study hepatitis c ribavirin therapy steatosi baseline t-cell virus decline outcome liver infection phase hcv rna concentration level signi interferon treatment outcome stage hepatitis c virus score allele il 28b university kinetic figure analysis guci score ficant ishak cirrhosis brosi rs 12979860 -10 hcv-speci group value fibrosis association hcv genotype 1 phase decline 24 weeks result body mass index plasma table peginterferon hcv-rna hepatology frequency hla-a fi brosis genotype 1 signi ficantly peptide index model biopsy ip -10 rs 8099917 trial impact fi rst month day 29 t-cell lines polymorphism il 28b polymorphisms hcv genotype 2 t-cell response signi ficant effect hla-a 2 non-rvr proliferative t-cell responses